Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 491

1.

Clinical impact of false-negative sentinel lymph nodes in breast cancer.

Zavagno G, Del Bianco P, Koussis H, Artioli G, Carraro P, De Salvo GL, Mencarelli R, Belardinelli V, Marconato G, Nitti D.

Eur J Surg Oncol. 2008 Jun;34(6):620-5. Epub 2007 Aug 30.

PMID:
17764888
2.

A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.

Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, Renier M, Racano C, Carraro P, Nitti D; GIVOM Trialists.

Ann Surg. 2008 Feb;247(2):207-13. doi: 10.1097/SLA.0b013e31812e6a73.

PMID:
18216523
3.

Stage migration in breast cancer: surgical decisions concerning isolated tumour cells and micro-metastases in the sentinel lymph node.

de Widt-Levert L, Tjan-Heijnen V, Bult P, Ruers T, Wobbes T.

Eur J Surg Oncol. 2003 Apr;29(3):216-20.

PMID:
12657229
4.

[Validation study of the sentinel lymph node (SLN) method in invasive breast carcinoma. Personal data and review of the literature].

Langer I, Zuber M, Köchli OR, Kocher T, Müller-Brand J, Torhorst J, Harder F.

Swiss Surg. 2000;6(3):128-36. Review. German.

PMID:
10894014
5.

Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.

Pernas S, Gil M, Benítez A, Bajen MT, Climent F, Pla MJ, Benito E, Guma A, Gutierrez C, Pisa A, Urruticoechea A, Pérez J, Gil Gil M.

Ann Surg Oncol. 2010 Mar;17(3):772-7.

PMID:
20183912
6.

Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer.

Chung MH, Ye W, Giuliano AE.

Ann Surg Oncol. 2001 Oct;8(9):688-92.

PMID:
11597008
7.

Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.

Yegiyants S, Romero LM, Haigh PI, DiFronzo LA.

Arch Surg. 2010 Jun;145(6):564-9. doi: 10.1001/archsurg.2010.84.

PMID:
20566977
8.

Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.

Goyal A, Newcombe RG, Chhabra A, Mansel RE.

Ann Surg Oncol. 2008 Jan;15(1):262-7. Epub 2007 Sep 19.

PMID:
17879117
9.

Sentinel lymph node micrometastasis as a predictor of axillary tumor burden.

Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R.

Breast J. 2004 Mar-Apr;10(2):101-5.

PMID:
15009035
10.

Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.

Langer I, Guller U, Hsu-Schmitz SF, Ladewig A, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M.

Eur J Surg Oncol. 2009 Aug;35(8):805-13. doi: 10.1016/j.ejso.2008.09.006. Epub 2008 Nov 28.

PMID:
19046846
11.

Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy.

Kinoshita T, Takasugi M, Iwamoto E, Akashi-Tanaka S, Fukutomi T, Terui S.

Am J Surg. 2006 Feb;191(2):225-9.

PMID:
16442950
12.

Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.

Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK.

Cancer. 2007 Apr 1;109(7):1255-63.

13.

Sentinel lymph node biopsy alone without axillary lymph node dissection--follow up of sentinel lymph node negative breast cancer patients.

Reitsamer R, Peintinger F, Prokop E, Menzel C, Cimpoca W, Rettenbacher L.

Eur J Surg Oncol. 2003 Apr;29(3):221-3.

PMID:
12657230
14.

Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasis.

Travagli JP, Atallah D, Mathieu MC, Rochard F, Camatte S, Lumbroso J, Garbay JR, Rouzier R.

Eur J Surg Oncol. 2003 May;29(4):403-6.

PMID:
12711299
15.

Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node.

Rivers AK, Griffith KA, Hunt KK, Degnim AC, Sabel MS, Diehl KM, Cimmino VM, Chang AE, Lucas PC, Newman LA.

Ann Surg Oncol. 2006 Jan;13(1):36-44. Epub 2006 Jan 1.

16.

Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer.

Takei H, Suemasu K, Kurosumi M, Horii Y, Yoshida T, Ninomiya J, Yoshida M, Hagiwara Y, Kamimura M, Hayashi Y, Inoue K, Tabei T.

Breast Cancer. 2007;14(1):16-24.

17.

Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.

Kiluk JV, Ly QP, Santillan AA, Meade T, Ramos D, Reintgen DS, Dessureault S, Davis M, Shamehdi C, Cox CE.

Ann Surg Oncol. 2010 Feb;17(2):552-7. doi: 10.1245/s10434-009-0800-2.

PMID:
19957043
18.

Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients.

Zavagno G, Carcoforo P, Franchini Z, Renier M, Barutta L, De Salvo GL, Maravegias K, Capitanio G, Nitti D, Lise M.

Eur J Surg Oncol. 2005 Sep;31(7):715-20.

PMID:
16005176
19.

Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.

Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W.

Ann Surg Oncol. 2006 Dec;13(12):1655-63. Epub 2006 Oct 3.

PMID:
17016755
20.

Axillary recurrences after negative sentinel lymph node biopsy under local anaesthesia for breast cancer: a follow-up study after 5 years.

Groetelaers RP, van Berlo CL, Nijhuis PH, Schapers RF, Gerritsen HA.

Eur J Surg Oncol. 2009 Feb;35(2):159-63. doi: 10.1016/j.ejso.2008.07.017. Epub 2008 Sep 11.

PMID:
18789841

Supplemental Content

Support Center